Center for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.
Section for Biomarkers, Immunology and Antibodies, Department for Congenital Disorders, Statens Serum Institut, Copenhangen, Denmark.
Nat Rev Gastroenterol Hepatol. 2024 Feb;21(2):86-100. doi: 10.1038/s41575-023-00854-4. Epub 2023 Nov 10.
Inflammatory bowel disease (IBD) is an immune-mediated inflammatory disease (IMID) of the gastrointestinal tract and includes two subtypes: Crohn's disease and ulcerative colitis. It is well-recognized that IBD is associated with a complex multifactorial aetiology that includes genetic predisposition and environmental exposures, with downstream dysregulation of systemic immune function and host-microbial interactions in the local environment in the gut. Evidence to support the notion of a multistage development of IBD is growing, as has been observed in other IMIDs such as rheumatoid arthritis and systemic lupus erythematosus. With the rising worldwide incidence of IBD, it is increasingly important to understand the complex interplay of pathological events during the different stages of disease development to enable IBD prediction and prevention strategies. In this article, we review comprehensively the current evidence pertaining to the preclinical phase of IBD, including at-risk, initiation and expansion phases. We also discuss the framework of preclinical IBD, expanding on underlying pathways in IBD development, future research directions and IBD development in the context of other IMIDs.
炎症性肠病(IBD)是一种胃肠道免疫介导的炎症性疾病(IMID),包括两种亚型:克罗恩病和溃疡性结肠炎。人们已经认识到,IBD 与复杂的多因素病因有关,包括遗传易感性和环境暴露,下游全身免疫功能失调和肠道内局部环境中的宿主-微生物相互作用。越来越多的证据支持 IBD 的多阶段发展的观点,正如在其他免疫介导的疾病(如类风湿关节炎和系统性红斑狼疮)中所观察到的那样。随着全球 IBD 的发病率不断上升,了解疾病发展的不同阶段的病理事件的复杂相互作用对于实现 IBD 的预测和预防策略变得越来越重要。在本文中,我们全面回顾了与 IBD 临床前阶段相关的现有证据,包括风险期、启动期和扩展期。我们还讨论了临床前 IBD 的框架,扩展了 IBD 发展过程中的潜在途径、未来的研究方向以及 IBD 在其他免疫介导的疾病中的发展。